EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS
Azithromycin
CLASS
Macrolide
MECHANISM OF ACTION
Bacteriostatic activity
DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)
Investigational
MODE OF ADMINISTRATION
Oral
LINK TO PUBMED
https://pubmed.ncbi.nlm.nih.gov/32091697/
https://pubmed.ncbi.nlm.nih.gov/28392809/
SIMILAR TARGETS IN OTHER SPECIES
23S ribosomal subunit ~ Enteric bacteria and other eubacteria
DRUG BANK ID
DB00207
EXTERNAL LINKS
Human Metabolome Database HMDB0014352
KEGG Compound C06838
PubChem Compound 447043
PubChem Substance 46507743
ChemSpider 10482163
BindingDB 50373918
RxNav 1299904
ChEBI 2955
ChEMBL CHEMBL529
ZINC ZINC000085537026
Drugs.com Drugs.com Drug Page https://www.drugs.com/cdi/azithromycin-drops.html
Wikipedia Azithromycin
REFERENCE
Owusu, E., Newman, M. J., Addo, K. K., & Addo, P. (2017). In Vitro Susceptibility of Mycobacterium ulcerans Isolates to Selected Antimicrobials. The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses et de La Microbiologie Médicale, 2017. https://doi.org/10.1155/2017/5180984
Pluschke, G., & Röltgen, K. (2019). Buruli ulcer: Mycobacterium ulcerans disease. In Buruli Ulcer: Mycobacterium ulcerans Disease. https://doi.org/10.1007/978-3-030-11114-4